In sum, our data support the existence of clinically significant intertumor and intratumor heterogeneity within NF1-mutant, IDH wild-type glioblastoma with distinct responses to the MEK inhibitor selumetinib. This evidence concerns the gene MAP2K7 and glioblastoma.